Mei Pharma, Common Stock Current Asset
| LITS Stock | 2.08 0.15 7.77% |
Fundamental analysis of MEI Pharma, allows traders to better anticipate movements in MEI Pharma,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
Non Current Assets Total is expected to grow at the current pace this year. Other Current Assets is likely to drop to about 260.3 K in 2025. MEI | Current Asset | Build AI portfolio with MEI Stock |
MEI Pharma, Common Company Current Asset Analysis
MEI Pharma,'s Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
MEI Current Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for MEI Pharma, is extremely important. It helps to project a fair market value of MEI Stock properly, considering its historical fundamentals such as Current Asset. Since MEI Pharma,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MEI Pharma,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MEI Pharma,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, MEI Pharma, Common has a Current Asset of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Asset (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
MEI Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MEI Pharma,'s direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MEI Pharma, could also be used in its relative valuation, which is a method of valuing MEI Pharma, by comparing valuation metrics of similar companies.MEI Pharma, is currently under evaluation in current asset category among its peers.
MEI Fundamentals
| EBITDA | (17.09 M) | |||
| Net Income | (15.95 M) | |||
| Total Debt | 1.35 M | |||
| Cash Flow From Operations | (20.84 M) | |||
| Total Asset | 18.29 M | |||
| Retained Earnings | (404.16 M) | |||
| Working Capital | 16.93 M | |||
| Net Asset | 18.29 M |
About MEI Pharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MEI Pharma, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MEI Pharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MEI Pharma, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MEI Stock Analysis
When running MEI Pharma,'s price analysis, check to measure MEI Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma, is operating at the current time. Most of MEI Pharma,'s value examination focuses on studying past and present price action to predict the probability of MEI Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma,'s price. Additionally, you may evaluate how the addition of MEI Pharma, to your portfolios can decrease your overall portfolio volatility.